Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice

Kulu, Yakup; Dorfman, Jon D.; Kuruppu, Darshini; Fuchs, Bryan C.; Goodwin, Jonathan M.; Fujii, Tsutomu; Kuroda, Toshihiko; Lanuti, Michael; Tanabe, Kenneth K.

doi:10.1038/cgt.2008.83

Cited by 31 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Kulu et al compared intraperitoneal to intravenous administration of oHSV to treat disseminated peritoneal colorectal carcinomatosis in mice (67). After three doses, these researchers found that intraperitoneal administration resulted in more restricted biodistribution, less host toxicity, and greater efficacy against peritoneal metastases compared with intravenous administration (67).…”

Section: Preclinical Successmentioning

confidence: 99%

Regional Liver Therapy Using Oncolytic Virus to Target Hepatic Colorectal Metastases

Carpenter

Carson

Fong

2010

Seminars in Oncology

View full text Add to dashboard Cite

The mortality of colorectal carcinoma often results from the progression of metastatic disease, which is predominantly hepatic. Though recent advances in surgical, locoregional, and systemic therapies have yielded modest survival improvements, treatment of these aggressive lesions is limited to palliation for the vast majority of patients. Oncolytic viral therapy represents a promising novel therapeutic modality that has achieved tumor regression in several preclinical and clinical models. Evidence further suggests that locoregional viral administration may improve viral efficacy while minimizing toxicity. This study will review the theories behind hepatic arterial infusion of oncolytic virus, as well as herpes viral design, preclinical data, and clinical progress in regional liver therapy using oncolytic virus to treat hepatic colorectal carcinoma metastases.

show abstract

Section: Preclinical Successmentioning

confidence: 99%

Regional Liver Therapy Using Oncolytic Virus to Target Hepatic Colorectal Metastases

Carpenter

Carson

Fong

2010

Seminars in Oncology

View full text Add to dashboard Cite

show abstract

“…7,[12][13][14][15] Patients with disseminated metastases of cancer frequently have other systemic metastases in tissues including the liver and lungs, and it is very important to deliver the viruses systemically to these metastatic sites. 17 However, Kulu et al 18 reported that i.p. administration was significantly more effective than i.v.…”

Section: Discussionmentioning

confidence: 99%

“…treated and control groups. 18 As viruses adhere nonspecifically to the endothelium and are neutralized by the immune system, viral titers at the target site may be insufficient in cases of i.v. administration.…”

Section: Introductionmentioning

confidence: 99%

Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes

et al. 2012

Self Cite

View full text Add to dashboard Cite

Although several studies have reported that locally administering oncolytic viruses effectively targets malignancies, the efficacy of systemically administered oncolytic viruses is restricted. Recently, however, it was reported that systemic administration of oncolytic vesicular stomatitis virus adsorbed onto antigen-specific lymphocytes was effective against malignancies. We hypothesized that intravenously administering such virus might have significant potential in treatment of the malignant tumors. We adsorbed oncolytic herpes simplex virus-1 mutant R3616 onto lymphocytes harvested from mice with acquired antitumor immunity. We administered adsorbed R3616 to peritoneally disseminated tumors and analyzed the efficacy of this treatment. Mice administered adsorbed R3616 survived significantly longer than mice administered R3616 adsorbed onto non-specific lymphocytes, or mice administered either virus or tumor antigen-specific lymphocytes alone. In this context, herpes oncolytic virus is a promising treatment not only for primary lesions, but also for multiple metastasizing lesions. This treatment strategy may become one of the most effective methods for systemic virus delivery.

show abstract

“…Previous studies typically used either intratumoral injection of oHSV into solid tumor lesions or systemic injection of high-dose oHSV (19,29,30). Given the multiple metastatic melanoma lesions in the brain, intratumoral injection into each single lesion is not a feasible approach.…”

Section: Discussionmentioning

confidence: 99%

Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas

Seah

Bougazzoul

et al. 2017

Proc. Natl. Acad. Sci. U.S.A.

102

View full text Add to dashboard Cite

The recent Food and Drug Administration approval of immunogenic oncolytic virus (OV) has opened a new era in the treatment of advanced melanoma; however, approximately 50% of patients with melanoma develop brain metastasis, and currently there are no beneficial treatment options for such patients. To model the progression of metastases seen in patients and to overcome the hurdles of systemic delivery of OV, we developed melanoma brain metastasis models in immunocompromised and immunocompetent mice, and tested the fate and efficacy of oncolytic herpes simplex virus (oHSV)-armed mesenchymal stem cells (MSCs). Using brain-seeking patient-derived melanoma cells and real-time in vivo imaging, we show a widespread distribution of micrometastases and macrometastases in the brain, recapitulating the progression of multifoci metastases seen in patients. We armed MSCs with different oHSV variants (MSC-oHSV) and found that intracarotid administration of MSC-oHSV, but not of purified oHSV alone, effectively tracks metastatic tumor lesions and significantly prolongs the survival of brain tumor-bearing mice. In a syngeneic model of melanoma brain metastasis, a combination of MSC-oHSV and PD-L1 blockade increases IFNγ-producing CD8 + tumor-infiltrating T lymphocytes and results in a profound extension of the median survival of treated animals. This study thus demonstrates the utility of MSCs as OV carriers to disseminated brain lesions, and provides a clinically applicable therapeutic platform to target melanoma brain metastasis.stem cells | oncolytic virus | tumors | metastasis | imaging M elanoma, the most aggressive type of skin cancer, accounts for a large proportion of skin cancer-related deaths (1). Among all cancer types, melanoma has a particularly high propensity to metastasize to the brain, occurring in >50% of all patients with advanced disease. More than 90% of melanoma brain metastases lead to death, and the median survival is 17-22 wk after detection (2-4).Current therapeutic options of chemotherapy, surgery, and radiation have very limited efficacy for patients with melanoma brain metastasis (5-7). These patients either have multiple metastatic lesions or diagnostically challenging asymptomatic lesions, making surgery an inadequate therapeutic option by itself. In addition, the blood-brain barrier (BBB) limits central nervous system (CNS) penetration of systemic therapies, and the negative side effects of radiotherapy (8) pose challenges for the success of existing therapies, contributing to the failure to improve overall patient survival. As such, there is an urgent need for new therapies for melanoma brain metastasis.The development and characterization of preclinical tumor models that authentically recapitulate the clinical disease settings are critical for developing and testing new therapies. Most previous studies have used either subcutaneous (s.c.) injection or intracranial injection of established melanoma lines in mice (9-11), which do not mimic the actual clinical settings of melanoma brain metastasis,...

show abstract

Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice

Cited by 31 publications

References 33 publications

Regional Liver Therapy Using Oncolytic Virus to Target Hepatic Colorectal Metastases

Regional Liver Therapy Using Oncolytic Virus to Target Hepatic Colorectal Metastases

Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes

Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas

Contact Info

Product

Resources

About